Talazoparib is approved for the treatment of germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, with ongoing studies exploring its efficacy in ovarian cancer. This evidence concerns the gene ERBB2 and breast carcinoma.